Abstract
Inhibition of CCR2 has been considered as a target for multiple therapeutic diseases including autoimmune disease, atherosclerosis, pain, and metabolic disease, based in part on the critical role this receptor plays on monocyte migration. Numerous companies have reported programs to identify CCR2 antagonists. Common challenges to the development of CCR2 agents have included poor activity at the rodent receptor and selectivity for both other chemokine receptors and ion channels. This review summarizes the rationale for targeting CCR2 in disease, the recent progress in the identification of potent and select CCR2 antagonists, and the current status of clinical trials for CCR2 agents.
Keywords: CCR2, autoimmune disease, atherosclerosis, metabolic disease, receptors, CCR2 antagonists
Current Topics in Medicinal Chemistry
Title: CCR2 Antagonists
Volume: 10 Issue: 13
Author(s): Mary Struthers and Alexander Pasternak
Affiliation:
Keywords: CCR2, autoimmune disease, atherosclerosis, metabolic disease, receptors, CCR2 antagonists
Abstract: Inhibition of CCR2 has been considered as a target for multiple therapeutic diseases including autoimmune disease, atherosclerosis, pain, and metabolic disease, based in part on the critical role this receptor plays on monocyte migration. Numerous companies have reported programs to identify CCR2 antagonists. Common challenges to the development of CCR2 agents have included poor activity at the rodent receptor and selectivity for both other chemokine receptors and ion channels. This review summarizes the rationale for targeting CCR2 in disease, the recent progress in the identification of potent and select CCR2 antagonists, and the current status of clinical trials for CCR2 agents.
Export Options
About this article
Cite this article as:
Struthers Mary and Pasternak Alexander, CCR2 Antagonists, Current Topics in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/156802610791561255
DOI https://dx.doi.org/10.2174/156802610791561255 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs
Current Medicinal Chemistry Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Modeling Inflammatory Bowel Disease by Intestinal Organoids
Recent Advances in Inflammation & Allergy Drug Discovery Central Self - Tolerance by Thymic Presentation of Self - Antigens and Autoimmunity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Acquired Hemophilia as Initial Presentation in a Patient with Systemic Lupus Erythematosus
Current Rheumatology Reviews Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives
Current Drug Targets Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry